Spillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer
Cancer Medicine · 2025
DOI: 10.1002/cam4.70796 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Arnav Srivastava und 13 weiteren Autor:innen. Beteiligte Einrichtung: Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Medicare Part C. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Introduction
Medicare Advantage (MA) managed care plans, now chosen by 51% of Medicare beneficiaries, are incentivized to constrain healthcare spending and utilization, a shift in financial incentives compared to Traditional Medicare's fee‐for‐service payment model. Beyond its primary beneficiaries, MA's mechanisms to constrain utilization may impact Traditional Medicare beneficiaries with prostate cancer through “spillover” effects on physician behavior.
Methods
From a 20% sample of Medicare claims, we identified patients diagnosed with prostate cancer from 2016 to 2019. We calculated MA penetration [MA beneficiaries/(Traditional Medicare and MA beneficiaries)] at the practice‐level. We assessed the relationship between practice‐level MA penetration and two measures of quality—potential overtreatment (i.e., treatment among those with > 75% noncancer mortality within 10 years of diagnosis) and confirmatory testing (repeat prostate biopsy, MRI, or genomic test)—using a multilevel logistic regression. We also assessed two measures of utilization, price standardized spending (i.e., global utilization) and overall treatment.
Results
We identified 41,092 patients. Median practice‐level MA penetration was 33% (IQR 23%–43%). Increasing practice‐level MA penetration was associated with increased odds of overall treatment among all Traditional Medicare beneficiaries (adjusted OR 1.03 (95% CI 1.01–1.05), p = 0.01, per 10% increase in MA penetration). However, MA penetration was not associated with our quality measures, potential overtreatment and confirmatory testing, or price‐standardized spending.
Conclusions
MA penetration at the urology practice‐level varies considerably. In men with prostate cancer, greater practice‐level MA penetration was associated with increased odds of treatment, but not overall utilization—even where it might influence quality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Urology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
ORCID-Profile: Arnav Srivastava, Addison Shay, Kassem S Faraj, Paula Guro, Lindsey A Herrel
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Srivastava, A., Kaufman, S. R., Liu, X., Maganty, A., Shay, A., Oerline, M., Dall, C., Faraj, K. S., Guro, P., Hill, D., Nguyen, T., Herrel, L. A., Hollenbeck, B. K., & Shahinian, V. B. (2025). Spillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70796
Vancouver
Srivastava A, Kaufman SR, Liu X, Maganty A, Shay A, Oerline M, et al. Spillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.70796
BibTeX
@article{Srivastava2025,
author = {Srivastava, Arnav and Kaufman, Samuel R and Liu, Xiu and Maganty, Avinash and Shay, Addison and Oerline, Mary and Dall, Christopher and Faraj, Kassem S and Guro, Paula and Hill, Dawson and Nguyen, Thuy and Herrel, Lindsey A and Hollenbeck, Brent K and Shahinian, Vahakn B},
title = {Spillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70796}
}
EUVIMED